- Home
- SSSS vs GALT Comparison
SSSS vs GALT Comparison
Compare SSSS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- GALT
- Stock Information
- Founded
- SSSS 2010
- GALT 2000
- Country
- SSSS United States
- GALT United States
- Employees
- SSSS N/A
- GALT N/A
- Industry
- SSSS Finance: Consumer Services
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- SSSS Finance
- GALT Health Care
- Exchange
- SSSS Nasdaq
- GALT Nasdaq
- Market Cap
- SSSS 227.8M
- GALT 232.3M
- IPO Year
- SSSS N/A
- GALT N/A
- Fundamental
- Price
- SSSS $10.11
- GALT $5.60
- Analyst Decision
- SSSS Strong Buy
- GALT Strong Buy
- Analyst Count
- SSSS 4
- GALT 3
- Target Price
- SSSS $10.13
- GALT $6.00
- AVG Volume (30 Days)
- SSSS 255.7K
- GALT 357.5K
- Earning Date
- SSSS 11-04-2025
- GALT 11-14-2025
- Dividend Yield
- SSSS 9.99%
- GALT N/A
- EPS Growth
- SSSS N/A
- GALT N/A
- EPS
- SSSS 2.60
- GALT N/A
- Revenue
- SSSS $2,354,933.00
- GALT N/A
- Revenue This Year
- SSSS $7,183.09
- GALT N/A
- Revenue Next Year
- SSSS N/A
- GALT N/A
- P/E Ratio
- SSSS $3.84
- GALT N/A
- Revenue Growth
- SSSS N/A
- GALT N/A
- 52 Week Low
- SSSS $4.21
- GALT $0.73
- 52 Week High
- SSSS $10.34
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- SSSS 63.88
- GALT 61.86
- Support Level
- SSSS $9.68
- GALT $5.55
- Resistance Level
- SSSS $10.23
- GALT $6.25
- Average True Range (ATR)
- SSSS 0.34
- GALT 0.35
- MACD
- SSSS 0.09
- GALT 0.03
- Stochastic Oscillator
- SSSS 82.45
- GALT 58.11
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.